CD19/BCMA CAR T-cells is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Chengdu Ucello Biotechnology Co., Ltd. (1) and Essen Biotech (1). Registered phases: Phase EARLY_PHASE1 and Phase 1/2. Conditions studied include SLE - Systemic Lupus Erythematosus; Systemic Lupus Erythematosus; Lupus Nephritis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06350110 | Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) (ClinicalTrials.gov ↗) Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases |
Phase 1/2 | Recruiting |
| NCT07266337 | CD19/BCMA CAR-T for SLE (ClinicalTrials.gov ↗) SLE - Systemic Lupus Erythematosus |
Phase EARLY_PHASE1 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| SLE - Systemic Lupus Erythematosus | 1 |
| Systemic Lupus Erythematosus | 1 |
| Lupus Nephritis | 1 |
| Autoimmune Diseases | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Lead sponsor | Trials |
|---|---|
| Chengdu Ucello Biotechnology Co., Ltd. | 1 |
| Essen Biotech | 1 |
| Register | CD19/BCMA CAR T-cells trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CD19/BCMA CAR T-cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD19/BCMA CAR T-cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.